Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation Research
Search: search_blue_button Advanced Search
Circulation Research. 2005;96:815-817
Published online before print March 24, 2005, doi: 10.1161/01.RES.0000163981.97262.3b
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
96/8/815    most recent
01.RES.0000163981.97262.3bv1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ziolo, M. T.
Right arrow Articles by Pogwizd, S. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ziolo, M. T.
Right arrow Articles by Pogwizd, S. M.
Related Collections
Right arrow Contractile function
Right arrow Congestive
Right arrow Animal models of human disease
Right arrow Calcium cycling/excitation-contraction coupling
Right arrow Heart failure - basic studies
Right arrow Gene therapy
(Circulation Research. 2005;96:815.)
© 2005 American Heart Association, Inc.


Report

Adenoviral Gene Transfer of Mutant Phospholamban Rescues Contractile Dysfunction in Failing Rabbit Myocytes With Relatively Preserved SERCA Function

Mark T. Ziolo, Jody L. Martin, Julie Bossuyt, Donald M. Bers, Steven M. Pogwizd

From the Department of Physiology (M.T.Z., J.L.M., J.B., D.M.B.), Loyola University Chicago, Maywood, Ill; and the Department of Medicine (S.M.P.), University of Illinois at Chicago, Chicago, Ill.

Correspondence to Mark T. Ziolo, Department of Physiology and Cell Biology, Ohio State University, 304 Hamilton Hall, 1645 Neil Ave, Columbus, OH 43210-1218. E-mail ziolo.1{at}osu.edu

In heart failure (HF) a main factor in reduced contractility is reduced SR Ca2+ content and reversed force-frequency response (FFR), ie, from positive to negative. Our arrhythmogenic rabbit HF model exhibits decreased contractility mainly due to an increase in Na/Ca exchange (NCX) activity (with only modest decrease in SR Ca2+-ATPase (SERCA) function), similar to many end-stage HF patients. Here we test whether phospholamban (PLB) inhibition using a dominant-negative mutant PLB adenovirus (K3E/R14E, AdPLB-dn, with ß-galactosidase adenovirus as control) could enhance SERCA function and restore Ca2+ transients and positive FFR in ventricular myocytes from these HF rabbits. HF myocytes infected with AdPLB-dn (versus control) had enhanced Ca2+ transient amplitude (2.0±0.1 versus 1.6±0.05 F/Fo at 0.5 Hz, P<0.05) and had a positive FFR, whereas acutely isolated HF myocytes or those infected with Adßgal had negative FFR. Ca2+ transients declined faster in AdPLB-dn versus Adßgal myocytes (RT50%: 317±29 versus 551±90 ms at 0.5 Hz, P<0.05) and had an increased SR Ca2+ load (3.5±0.3 versus 2.6±0.2 F/Fo at 0.5 Hz, P<0.05), indicative of increased SERCA function. Furthermore, this restoration of function was not due to changes in NCX or SERCA expression. Thus, increasing SERCA activity in failing myocytes by AdPLB-dn gene transfer reversed the contractile dysfunction (and restored positive FFR) by increasing SR Ca2+ load. This approach could enhance contractile function in failing hearts of various etiologies, even here where reduced SERCA activity is not the main dysfunction.


Key Words: heart failure • gene transfer • SERCA • phospholamban




This article has been cited by other articles:


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
J. R. Waggoner, K. S. Ginsburg, B. Mitton, K. Haghighi, J. Robbins, D. M. Bers, and E. G. Kranias
Phospholamban overexpression in rabbit ventricular myocytes does not alter sarcoplasmic reticulum Ca transport
Am J Physiol Heart Circ Physiol, March 1, 2009; 296(3): H698 - H703.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
J. Davis, M. V. Westfall, D. Townsend, M. Blankinship, T. J. Herron, G. Guerrero-Serna, W. Wang, E. Devaney, and J. M. Metzger
Designing Heart Performance by Gene Transfer
Physiol Rev, October 1, 2008; 88(4): 1567 - 1651.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
S. Nattel, A. Maguy, S. Le Bouter, and Y.-H. Yeh
Arrhythmogenic Ion-Channel Remodeling in the Heart: Heart Failure, Myocardial Infarction, and Atrial Fibrillation
Physiol Rev, April 1, 2007; 87(2): 425 - 456.
[Abstract] [Full Text] [PDF]


Home page
J CARDIOVASC PHARMACOL THERHome page
M. A. Nordlie, L. E. Wold, B. Z. Simkhovich, C. Sesti, and R. A. Kloner
Molecular Aspects of Ischemic Heart Disease: Ischemia/Reperfusion-Induced Genetic Changes and Potential Applications of Gene and RNA Interference Therapy
Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2006; 11(1): 17 - 30.
[Abstract] [PDF]


Home page
J. Biol. Chem.Home page
G. J. Babu, P. Bhupathy, N. N. Petrashevskaya, H. Wang, S. Raman, D. Wheeler, G. Jagatheesan, D. Wieczorek, A. Schwartz, P. M. L. Janssen, et al.
Targeted Overexpression of Sarcolipin in the Mouse Heart Decreases Sarcoplasmic Reticulum Calcium Transport and Cardiac Contractility
J. Biol. Chem., February 17, 2006; 281(7): 3972 - 3979.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
J. W.M. Bassani and R. A. Bassani
SERCA upregulation: Breaking the positive feedback in heart failure?
Cardiovasc Res, September 1, 2005; 67(4): 581 - 582.
[Full Text] [PDF]